Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Chest. 2020 Jul;158(1):e9-e13. doi: 10.1016/j.chest.2020.03.039. Epub 2020 Mar 31.

Abstract

As of March 24, 2020, novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been responsible for 379,661 infection cases with 16,428 deaths globally, and the number is still increasing rapidly. Herein, we present four critically ill patients with SARS-CoV-2 infection who received supportive care and convalescent plasma. Although all four patients (including a pregnant woman) recovered from SARS-CoV-2 infection eventually, randomized trials are needed to eliminate the effect of other treatments and investigate the safety and efficacy of convalescent plasma therapy.

Keywords: SARS-CoV-2; convalescent plasma; critical illness.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Aged
  • Antifungal Agents / administration & dosage
  • Antiviral Agents* / administration & dosage
  • Antiviral Agents* / classification
  • Betacoronavirus / isolation & purification
  • COVID-19
  • COVID-19 Testing
  • Clinical Laboratory Techniques / methods
  • Coronavirus Infections* / complications
  • Coronavirus Infections* / diagnosis
  • Coronavirus Infections* / physiopathology
  • Coronavirus Infections* / therapy
  • Critical Illness / therapy*
  • Extracorporeal Membrane Oxygenation / methods
  • Female
  • Humans
  • Immunization, Passive / methods
  • Male
  • Middle Aged
  • Pandemics*
  • Pneumonia, Viral* / complications
  • Pneumonia, Viral* / diagnosis
  • Pneumonia, Viral* / microbiology
  • Pneumonia, Viral* / physiopathology
  • Pneumonia, Viral* / therapy
  • Pregnancy
  • Pregnancy Complications, Infectious* / physiopathology
  • Pregnancy Complications, Infectious* / therapy
  • Pregnancy Complications, Infectious* / virology
  • Radiography, Thoracic / methods
  • Respiration, Artificial / methods
  • SARS-CoV-2
  • Tomography, X-Ray Computed / methods
  • Treatment Outcome

Substances

  • Antifungal Agents
  • Antiviral Agents

Supplementary concepts

  • COVID-19 serotherapy